✦ LIBER ✦

Efficacy of oral pentasa® 4g/day in treatment of active Crohn's disease: a meta-analysis double-blind, placebo-controlled trials

✍ Scribed by Hanauer, Stephen B.; Stromberg, Ulf

Book ID: 124104189
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 178 KB
Volume: 120
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(08)82247-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral pentasa in the treatment of active

Oral pentasa in the treatment of active Crohn?s disease: A meta-analysis of double-blind, placebo-controlled trials

✍ HANAUER, S 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 132 KB

Prevention of relapse by mesalazine (Pen

Prevention of relapse by mesalazine (Pentasa®) in pediatric Crohn's disease: A multicenter, double-blind, randomized, placebo-controlled trial

✍ J.-P. Cezard; A. Munck; O. Mouterde; A. Morali; C. Lenaerts; A. Lachaux; D. Turc 📂 Article 📅 2009 🏛 Masson Editeur 🌐 French ⚖ 961 KB

Efficacy of oral long-term N-acetylcyste

Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebo-controlled clinical trials

✍ Etienne M. Grandjean; Philippe Berthet; Ralf Ruffmann; Philippe Leuenberger 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 794 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease

✍ J. C. MANSFIELD; M. PARKES; A. B. HAWTHORNE; A. FORBES; C. S. J. PROBERT; R.C. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 563 KB

S1066 Oral Alpha-4 Integrin Inhibitor (A

S1066 Oral Alpha-4 Integrin Inhibitor (AJM300) in Patients with Active Crohn's Disease — A Randomized, Double-Blind, Placebo-Controlled Trial

✍ Masakazu Takazoe; Mamoru Watanabe; Takaaki Kawaguchi; Takayuki Matsumoto; Nobuhi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 100 KB

Randomized, double-blind, placebo-contro

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease

✍ Bruce E. Sands; Eric W. Jacobson; Thomas Sylwestrowicz; Ziad Younes; Gerald Dryd 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 349 KB 👁 1 views

## Background: Interleukin-12 (il-12) and interleukin-23 (il-23) are inflammatory cytokines linked to the th-1 and th-17 phenotypes associated with crohn's disease (cd). we investigated the activity and safety of apilimod mesylate (formerly sta-5326), an oral il-12 and il-23 inhibitor, in patients